1. Efficacy and Safety of Tinefcon® Tablets in Subjects with Plaque Psoriasis: An Open Label, Non-Comparative, Multicenter, Phase IV Trial
- Author
-
A. J. Kanwar, Puneet Goyal, Parag Kalyani, Sharmila Patil, Kailash Bhatia, Abhijeet Morde, Aruna Samarth, Ashish Suthar, Sanjeev Hegde, Rizwan Haq, Hitesh Khandagale, Dasiga Venkata Subrahmanya Pratap, Sudhakar Grandhi, Bhavesh Swarnakar, Sandesh Gupta, Leena Kansal, Yogesh Dound, D. G. Saple, Nitin Jadhav, Sujay Kulkarni, Murlidhara Padigaru, Vinod Titarmare, Somesh Sharma, Leelavathi Budamakuntla, Shatrughan Sahay, Ranjan C Rawal, Vikrant Saoji, Sushil Pande, and Meetesh Agarwal
- Subjects
0301 basic medicine ,Plaque psoriasis ,medicine.medical_specialty ,biology ,business.industry ,biology.organism_classification ,medicine.disease ,Phase IV Trial ,Surgery ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Psoriatic arthritis ,030104 developmental biology ,0302 clinical medicine ,Internal medicine ,Concomitant ,Sphaeranthus indicus ,Psoriasis ,Multicenter trial ,medicine ,Open label ,business - Abstract
Importance: This post-marketing surveillance study was conducted to evaluate real-world information about the efficacy and safety of oral Tinefcon? tablets (Sphaeranthus indicus based) in plaque psoriasis patients. Materials and Methods: Patients aged at least 18 years and older with clinical diagnosis of plaque psoriasis, were enrolled in this open label, non-comparative, multicenter trial. All eligible subjects received four 700 mg Tinefcon? tablets/day for 12 weeks. The primary outcome measure was percent change in Psoriasis Area Severity Index (PASI) score from baseline to week 12. The secondary outcome measures were Physician Global Assessment (PGA), Nail Psoriasis Severity Index (NAPSI), Psoriatic Arthritis Evaluation and Gene Expression Profiling and Immunohistochemistry. Results: After completion of Tinefcon? treatment at 12 weeks, more than half of subjects (52%) achieved PASI 50 response; PASI 75 response was attained in 68 (23%) subjects and PASI 90 response in 22 (7%) subjects. Five subjects with severe psoriasis achieved PASI 90 without receiving any concomitant medication. Reduction in severity as assessed by PGA was observed in more than half of patients with moderate disease. Histopathological evaluation revealed that epidermal thickness was considerably reduced in 66% of subjects. The expression of inflammatory marker S100A9 protein was(meaningfully reduced in 60% patients with non-significant reduction of Keratin 10 protein expression. Gene expression analysis showed increase down regulation of SERPINB4; PI3 and KRT16 genes after a 12-week treatment period in subjects with higher PASI scores. Conclusion: Oral Tinefcon? tablets showed good efficacy and had a favorable safety profile in plaque psoriasis patients.
- Published
- 2016
- Full Text
- View/download PDF